Alto Neuroscience, Inc. (NYSE:ANRO) filed a Form 8-K on August 27, 2026, reporting the promotion of Nicholas C. Smith from Chief Financial Officer and Chief Business Officer to President and Chief Financial Officer, effective August 26, 2026, along with a $6,000,000 cash retention agreement.

Key Highlights

  • New title: Nicholas C. Smith was promoted to President and Chief Financial Officer, effective August 26, 2026.
  • CEO role unchanged: Amit Etkin, M.D., Ph.D. continues as Chief Executive Officer but no longer holds the office of President.
  • Retention payment - first tranche: $3,000,000 payable within ten days of the August 26, 2026 effective date.
  • Retention payment - second tranche: $3,000,000 payable on the twelve-month anniversary of the effective date.
  • Recoupment clause: If Mr. Smith departs before the two-year anniversary of the effective date, unpaid portions are forfeited and previously paid amounts are subject to recoupment within 30 days of his last day of employment.
  • Emerging growth company: Alto Neuroscience is designated an emerging growth company under applicable SEC rules.

Alto Neuroscience Executive Restructuring and Smith Retention Agreement Details

According to the filing, the Board of Directors of Alto Neuroscience, Inc. approved the promotion of Nicholas C. Smith on August 26, 2026. Mr. Smith, who previously served as Chief Financial Officer and Chief Business Officer, assumed the role of President and Chief Financial Officer immediately upon the board's action. Concurrently, Amit Etkin, M.D., Ph.D. relinquished the title of President while retaining his position as Chief Executive Officer and serving as the company's principal executive officer. Mr. Smith continues as the company's principal financial officer.

In connection with the promotion, the company entered into a Promotion and Retention Agreement with Mr. Smith on the same date. The agreement provides for a total cash retention payment of $6,000,000, structured in two equal installments of $3,000,000 each. The first installment is payable within ten days of August 26, 2026, and the second is payable on the twelve-month anniversary of that date. Both portions are stated to be "subject to standard deductions and withholdings," according to the filing.

The filing discloses that if Mr. Smith's employment ends for any reason, including resignation or termination for Cause, before the two-year anniversary of the effective date, he forfeits any unpaid retention amounts and must repay previously received amounts within 30 days of his last day. If the company terminates his employment without Cause, or if his employment ends due to death or Disability before that two-year mark, the company will pay any remaining unpaid portion. The filing also states there are no family relationships between Mr. Smith and any director or executive officer, and no arrangements or understandings with other persons related to his appointment.

What Was Disclosed

Alto Neuroscience disclosed a leadership title change elevating Nicholas C. Smith to President and CFO, a $6,000,000 structured retention payment, and the terms under which those payments may be forfeited or recouped, all effective August 26, 2026.